17,261 trials
Leukemia · Lymphoma · Multiple Myeloma and Plasma Cell Neoplasm
Primary: Number of Participants With Engraftment Failure — 1 Participants
ER+ and AR+ Breast Cancer
Primary: Clinical Benefit Rate, in Centrally Confirmed Androgen Receptor (AR)+ Subjects — 16; 15 participants
Ovarian Cancer · Fallopian Tube Cancer · Peritoneal Cancer
Primary: Overall Response Rate Per RECIST Version 1.1 (Part 2) — 25; 7 Participants
Candidemia · Mycoses · Fungal Infection
Primary: Incidence of Treatment Emergent Adverse Events [Safety and Tolerability] — 71; 49; 55 Participants
Cancer · Skin Fibroblasts · Muscle Weakness
Primary: Change in PCr Recovery Tc Measurement From Baseline to 12 Week NR Supplementation Using the 31P-MRS Skeletal Muscle Submaximal Exercise. — 60; 73 Seconds
Diabetic Macular Edema
Primary: BCVA — 0.8; -0.3; -1.8 Letters
Acute Myeloid Leukemia · Myelodysplastic Syndrome · Chronic Myeloid Leukemia
Primary: Participants With a Response — 4; 9; 16; 2 participants
Intraventricular Hemorrhage · Periventricular Leukomalacia · Brain Injury
Primary: Percent of Survivors With no Severe IVH (Grades 3 or 4) or PVL — 22.2; 14.9; 17.1; 10.9 percent of participants
Menopause · Hot Flashes
Primary: Change in STAI-6 Score — 12.31; 11.85; 10.76; 11.69 score on STAI scale — p=.004
Chemotherapy-induced Nausea and Vomiting (CINV)
Primary: Area Under the Plasma Concentration Versus Time Curve From Time Zero to Infinity (AUC0-inf) of Netupitant — 4460; 3849; 17340; 7637 ng*hr/mL
Hepatocellular Carcinoma
Primary: Median Time to Progression (TTP) — 3.7 months
Relapsed/Refractory Classical Hodgkin's Lymphoma
Primary: Objective Response Rate (ORR) Assessed According to the Revised International Working Group Response Criteria for Malignant Lymphoma in 2007(IWG 2007) by the Independent…
Breast Cancer
Primary: Median Change in 6-month Tumor Volume Compared to Baseline Using Mammography — -5.0 change in tumor volume (mm) — p=0.07
Amyloidosis; Heart (Manifestation) · Senile Cardiac Amyloidosis
Primary: Changes in Strain Echocardiography — 9.1 percent LV shortening
Chronic Scar Pain
Primary: Time to Onset of Effect in the Spontaneous Numerical Rating Scale (NRS) Score — 4.41; 15.11; 29.45; 0.65 days